Head and Neck Squamous Cell Carcinoma — Trials

Head and Neck Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 592
Recruiting: 313
Ph III recruiting: 31
Growth YoY: +30.1%
Industry share: 28%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (247)

clinicaltrialsPublishedShowing 301–350 of 1,589 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00494182	Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	active not recruiting	Phase 2	48	M.D. Anderson Cancer CenterOTHER	1	Jun 12, 2026	clinicaltrials
NCT01154920	Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma	active not recruiting	Phase 2	128	M.D. Anderson Cancer CenterOTHER	1